UB Paderborn / Katalog / Suche / in CDI

Hippocampal dysfunction and cognitive impairments provoked by chronic early-life stress involve excessive activation of CRH receptors

The Journal of neuroscience, 2010-09, Vol.30 (39), p.13005-13015

2010

Link zum Volltext

Verfügbarkeit prüfen

Pharmacologic Characterization of Valbenazine (NBI-98854) and Its Metabolites

The Journal of pharmacology and experimental therapeutics, 2017-06, Vol.361 (3), p.454

2017

Link zum Volltext

Verfügbarkeit prüfen

The CRF1 Antagonist Verucerfont in Anxious Alcohol-Dependent Women: Translation of Neuroendocrine, But not of Anti-Craving Effects

Neuropsychopharmacology (New York, N.Y.), 2016-11, Vol.41 (12), p.2818-2829

2016

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of Vesicular Monoamine Transporter 2 Inhibition and Synergy with Antipsychotics in Animal Models of Schizophrenia

The Journal of pharmacology and experimental therapeutics, 2022-05, Vol.381 (2), p.79

2022

Link zum Volltext

Verfügbarkeit prüfen

Effects of NBI-98782, a selective vesicular monoamine transporter 2 (VMAT2) inhibitor, on neurotransmitter efflux and phencyclidine-induced locomotor activity: Relevance to tardive dyskinesia and antipsychotic action

Pharmacology, biochemistry and behavior, 2020-03, Vol.190, p.172872, Article 172872

2020

Link zum Volltext

Verfügbarkeit prüfen

CRF system recruitment mediates dark side of compulsive eating

Proceedings of the National Academy of Sciences - PNAS, 2009-11, Vol.106 (47), p.20016-20020

2009

Link zum Volltext

Verfügbarkeit prüfen

The importance of target binding kinetics for measuring target binding affinity in drug discovery: a case study from a CRF1 receptor antagonist program

Drug discovery today, 2020-01, Vol.25 (1), p.7-14

2020

Link zum Volltext

Verfügbarkeit prüfen

Binding kinetics redefine the antagonist pharmacology of the corticotropin-releasing factor type 1 receptor

The Journal of pharmacology and experimental therapeutics, 2012-05, Vol.341 (2), p.518

2012

Link zum Volltext

Verfügbarkeit prüfen

Single-Dose Study of a Corticotropin-Releasing Factor Receptor-1 Antagonist in Women With 21-Hydroxylase Deficiency

The journal of clinical endocrinology and metabolism, 2016-03, Vol.101 (3), p.1174-1180

2016

Link zum Volltext

Verfügbarkeit prüfen

International Union of Pharmacology. XXXVI. Current status of the nomenclature for receptors for corticotropin-releasing factor and their ligands

Pharmacological reviews, 2003-03, Vol.55 (1), p.21

2003

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetic and Pharmacologic Characterization of the Dihydrotetrabenazine Isomers of Deutetrabenazine and Valbenazine

Clinical pharmacology in drug development, 2023-04, Vol.12 (4), p.447-456

2023

Link zum Volltext

Verfügbarkeit prüfen

Human Endometriosis Is Associated with Plasma Cells and Overexpression of B Lymphocyte Stimulator

Proceedings of the National Academy of Sciences - PNAS, 2007-07, Vol.104 (30), p.12451-12456

2007

Link zum Volltext

Verfügbarkeit prüfen

Corticotropin-Releasing Hormone Receptor 2-Deficient Mice Have Reduced Intestinal Inflammatory Responses

Journal of Immunology, 2006-09, Vol.177 (5), p.3355-3361

2006

Link zum Volltext

Verfügbarkeit prüfen

CRF receptor type 1 and 2 expression and anatomical distribution in the rat colon

Journal of neurochemistry, 2004-07, Vol.90 (2), p.309-316

2004

Link zum Volltext

Verfügbarkeit prüfen

The corticotropin-releasing factor receptor: a novel target for the treatment of depression and anxiety-related disorders

Expert opinion on therapeutic targets, 2005-08, Vol.9 (4), p.651-684

Grigoriadis, Dimitri E

2005

Link zum Volltext

Verfügbarkeit prüfen

Modulation of Dendritic Differentiation by Corticotropin-Releasing Factor in the Developing Hippocampus

Proceedings of the National Academy of Sciences - PNAS, 2004-11, Vol.101 (44), p.15782-15787

2004

Link zum Volltext

Verfügbarkeit prüfen

Central CRF, urocortins and stress increase colonic transit via CRF1 receptors while activation of CRF2 receptors delays gastric transit in mice

The Journal of physiology, 2004-04, Vol.556 (1), p.221-234

2004

Link zum Volltext

Verfügbarkeit prüfen

VMAT2 Inhibitors and the Path to Ingrezza (Valbenazine)

Progress in medicinal chemistry, 2018, Vol.57 (1), p.87-111

2018

Link zum Volltext

Verfügbarkeit prüfen

Corticotropin-releasing factor receptor subtype 2 in human colonic mucosa: down-regulation in ulcerative colitis

World journal of gastroenterology : WJG, 2013-03, Vol.19 (9), p.1416-1423

2013

Link zum Volltext

Verfügbarkeit prüfen

Differences in Dihydrotetrabenazine Isomer Concentrations Following Administration of Tetrabenazine and Valbenazine

Drugs in R&D, 2017-09, Vol.17 (3), p.449-459

2017

Link zum Volltext

Verfügbarkeit prüfen

High-affinity CRF1 receptor antagonist NBI-34041 : Preclinical and clinical data suggest safety and efficacy in attenuating elevated stress response

Neuropsychopharmacology (New York, N.Y.), 2007-09, Vol.32 (9), p.1941-1949

2007

Link zum Volltext

Verfügbarkeit prüfen

Corticotropin-Releasing Factor and Urocortin I Modulate Excitatory Glutamatergic Synaptic Transmission

The Journal of neuroscience, 2004-04, Vol.24 (16), p.4020-4029

2004

Link zum Volltext

Verfügbarkeit prüfen

A novel water-soluble selective CRF1 receptor antagonist, NBI 35965, blunts stress-induced visceral hyperalgesia and colonic motor function in rats

Brain research, 2003-09, Vol.985 (1), p.32-42

2003

Link zum Volltext

Verfügbarkeit prüfen

Reduction of Stress-Induced Behavior by Antagonism of Corticotropin-Releasing Hormone 2 (CRH2) Receptors in Lateral Septum or CRH1 Receptors in Amygdala

The Journal of neuroscience, 2002-04, Vol.22 (7), p.2926-2935

2002

Link zum Volltext

Verfügbarkeit prüfen

Design of 2,5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7-dipropylamino-pyrazolo[1,5-a] pyrimidine (NBI 30775/r121919) and structure-activity relationships of a series of potent and orally active corticotropin-releasing factor receptor antagonists

Journal of medicinal chemistry, 2004-09, Vol.47 (19), p.4787-4798

2004

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Hippocampal dysfunction and cognitive impairments provoked by chronic early-life stress involve excessive activation of CRH receptors

Pharmacologic Characterization of Valbenazine (NBI-98854) and Its Metabolites

The CRF1 Antagonist Verucerfont in Anxious Alcohol-Dependent Women: Translation of Neuroendocrine, But not of Anti-Craving Effects

Efficacy of Vesicular Monoamine Transporter 2 Inhibition and Synergy with Antipsychotics in Animal Models of Schizophrenia

Effects of NBI-98782, a selective vesicular monoamine transporter 2 (VMAT2) inhibitor, on neurotransmitter efflux and phencyclidine-induced locomotor activity: Relevance to tardive dyskinesia and antipsychotic action

CRF system recruitment mediates dark side of compulsive eating

The importance of target binding kinetics for measuring target binding affinity in drug discovery: a case study from a CRF1 receptor antagonist program

Binding kinetics redefine the antagonist pharmacology of the corticotropin-releasing factor type 1 receptor

Single-Dose Study of a Corticotropin-Releasing Factor Receptor-1 Antagonist in Women With 21-Hydroxylase Deficiency

International Union of Pharmacology. XXXVI. Current status of the nomenclature for receptors for corticotropin-releasing factor and their ligands

Pharmacokinetic and Pharmacologic Characterization of the Dihydrotetrabenazine Isomers of Deutetrabenazine and Valbenazine

Human Endometriosis Is Associated with Plasma Cells and Overexpression of B Lymphocyte Stimulator

Corticotropin-Releasing Hormone Receptor 2-Deficient Mice Have Reduced Intestinal Inflammatory Responses

CRF receptor type 1 and 2 expression and anatomical distribution in the rat colon

The corticotropin-releasing factor receptor: a novel target for the treatment of depression and anxiety-related disorders

Modulation of Dendritic Differentiation by Corticotropin-Releasing Factor in the Developing Hippocampus

Central CRF, urocortins and stress increase colonic transit via CRF1 receptors while activation of CRF2 receptors delays gastric transit in mice

VMAT2 Inhibitors and the Path to Ingrezza (Valbenazine)

Corticotropin-releasing factor receptor subtype 2 in human colonic mucosa: down-regulation in ulcerative colitis

Differences in Dihydrotetrabenazine Isomer Concentrations Following Administration of Tetrabenazine and Valbenazine

High-affinity CRF1 receptor antagonist NBI-34041 : Preclinical and clinical data suggest safety and efficacy in attenuating elevated stress response

Corticotropin-Releasing Factor and Urocortin I Modulate Excitatory Glutamatergic Synaptic Transmission

A novel water-soluble selective CRF1 receptor antagonist, NBI 35965, blunts stress-induced visceral hyperalgesia and colonic motor function in rats

Reduction of Stress-Induced Behavior by Antagonism of Corticotropin-Releasing Hormone 2 (CRH2) Receptors in Lateral Septum or CRH1 Receptors in Amygdala

Design of 2,5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7-dipropylamino-pyrazolo[1,5-a] pyrimidine (NBI 30775/r121919) and structure-activity relationships of a series of potent and orally active corticotropin-releasing factor receptor antagonists

Suchergebnisse filtern